These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 8254497)

  • 21. Potential of Liposomes for Enhancement of Oral Drug Absorption.
    Daeihamed M; Dadashzadeh S; Haeri A; Akhlaghi MF
    Curr Drug Deliv; 2017; 14(2):289-303. PubMed ID: 26768542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
    Patel GV; Patel VB; Pathak A; Rajput SJ
    Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potentials of proniosomes for improving the oral bioavailability of poorly water-soluble drugs.
    Song S; Tian B; Chen F; Zhang W; Pan Y; Zhang Q; Yang X; Pan W
    Drug Dev Ind Pharm; 2015 Jan; 41(1):51-62. PubMed ID: 24111828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The bioavailability of orally administered drugs with special regard to the liver as a filter for foreign matter].
    Raaflaub J
    Schweiz Med Wochenschr; 1980 Mar; 110(10):354-62. PubMed ID: 7394464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation.
    Yeap YY; Trevaskis NL; Quach T; Tso P; Charman WN; Porter CJ
    Mol Pharm; 2013 May; 10(5):1874-89. PubMed ID: 23480483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intestinal permeation enhancers to improve oral bioavailability of macromolecules: reasons for low efficacy in humans.
    Maher S; Geoghegan C; Brayden DJ
    Expert Opin Drug Deliv; 2021 Feb; 18(2):273-300. PubMed ID: 32937089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selection of oral bioavailability enhancing formulations during drug discovery.
    Zheng W; Jain A; Papoutsakis D; Dannenfelser RM; Panicucci R; Garad S
    Drug Dev Ind Pharm; 2012 Feb; 38(2):235-47. PubMed ID: 21851310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral peptide and protein delivery: intestinal obstacles and commercial prospects.
    Smart AL; Gaisford S; Basit AW
    Expert Opin Drug Deliv; 2014 Aug; 11(8):1323-35. PubMed ID: 24816134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selecting oral bioavailability enhancing formulations during drug discovery and development.
    Leucuta SE
    Expert Opin Drug Discov; 2014 Feb; 9(2):139-50. PubMed ID: 24387781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formulation strategies to improve oral peptide delivery.
    Maher S; Ryan B; Duffy A; Brayden DJ
    Pharm Pat Anal; 2014 May; 3(3):313-36. PubMed ID: 24998290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro/in-vivo characterization of trans-resveratrol-loaded nanoparticulate drug delivery system for oral administration.
    Singh G; Pai RS
    J Pharm Pharmacol; 2014 Aug; 66(8):1062-76. PubMed ID: 24779896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intestinal permeation enhancers.
    Aungst BJ
    J Pharm Sci; 2000 Apr; 89(4):429-42. PubMed ID: 10737905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs.
    Hu L; Tang X; Cui F
    J Pharm Pharmacol; 2004 Dec; 56(12):1527-35. PubMed ID: 15563759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model.
    Paixão P; Gouveia LF; Morais JA
    Int J Pharm; 2012 Jun; 429(1-2):84-98. PubMed ID: 22449410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
    Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanocarrier systems for oral drug delivery: do we really need them?
    Bernkop-Schnürch A
    Eur J Pharm Sci; 2013 May; 49(2):272-7. PubMed ID: 23537503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs.
    Wang XQ; Zhang Q
    Eur J Pharm Biopharm; 2012 Oct; 82(2):219-29. PubMed ID: 22885229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Presystemic extraction: mechanisms and consequences.
    Greenblatt DJ
    J Clin Pharmacol; 1993 Jul; 33(7):650-6. PubMed ID: 8366190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate.
    Jia Z; Lin P; Xiang Y; Wang X; Wang J; Zhang X; Zhang Q
    Eur J Pharm Biopharm; 2011 Sep; 79(1):126-34. PubMed ID: 21658449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanocrystals for Improving Oral Bioavailability of Drugs: Intestinal Transport Mechanisms and Influencing Factors.
    Tian Z; Mai Y; Meng T; Ma S; Gou G; Yang J
    AAPS PharmSciTech; 2021 Jun; 22(5):179. PubMed ID: 34128132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.